Skip to main content

ADVERTISEMENT

Ericha Franey, PhD

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...
10/18/2020
10/08/2020
Background: The impact of possible tardive dyskinesia (TD) was assessed in RE KINECT, a real-world study of antipsychotic-treated outpatients. Based on clinician assessments, patients wer...
11/22/2019